Scientists test new Two-Pronged attack on aggressive blood cancer
NCT ID NCT06660563
Summary
This early-stage study is testing the safety of a new two-drug combination for people with aggressive B-cell lymphoma that has come back or stopped responding to standard treatments. The main goal is to find a safe and tolerable dose for future testing. Researchers will also check if the treatment shows any signs of helping to shrink the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, NON-HODGKIN are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Concord Hospital
Concord, 2139, Australia
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Hosp. Clinic de Barcelona
Barcelona, 08036, Spain
-
Hosp. Gral. Univ. Gregorio Maranon
Madrid, 28007, Spain
-
Hosp. Univ. 12 de Octubre
Madrid, 28041, Spain
-
Inst. Cat. Doncologia-H Duran I Reynals
L'Hospitalet de Llobregat, 08908, Spain
-
Macquarie University Hospital
North Ryde, 2109, Australia
-
National Taiwan University Hospital
Taipei, 100, Taiwan
-
St Vincents Hospital Melbourne
Fitzroy, 3065, Australia
-
University Hospitals Of Leicester Nhs Trust
Leicester, Le1 5ww, United Kingdom
Conditions
Explore the condition pages connected to this study.